New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GSK;AAPL;BEN;GE;AZN;DELL From The Last 14 Days
Check below for free stories on GSK;AAPL;BEN;GE;AZN;DELL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
July 16, 2014
09:37 EDTAAPLActive equity options trading on open
Subscribe for More Information
09:37 EDTAAPLPhoto claims to show iPhone 6 Touch ID component, Business Insider says
Subscribe for More Information
09:35 EDTGEChina's 9 Air places $3.7B CFM engine order
Subscribe for More Information
09:23 EDTAAPLOn The Fly: Pre-market Movers
HIGHER: Time Warner (TWX), up 15% after company confirmed that it rejected an $80B takeover offer from 21st Century Fox (FOX, FOXA), as had been reported earlier this morning... Apple (AAPL), up 2% after announcing an enterprise mobile partnership with IBM (IBM), which is also up 2%... International Game (IGT), up 9.5% after agreeing to be acquired by GTECH for $4.7B in cash and stock... FireEye (FEYE), up 5% after shares upgraded at Goldman... Precision Drilling (PDS), up 4% after announcing strategic agreement with Schlumberger (SLB), upgraded at Deutsche Bank... Mellanox (MLNX), up 4.7% following upgrade at Jefferies. UP AFTER EARNINGS: Intel (INTC), up 5.4%... HCA Holdings (HCA), up 6%... Textron (TXT), up 3.2%... Abbott (ABT), up 1%. DOWN AFTER EARNINGS: PNC Financial (PNC), down 2.5%... MGIC Investment (MTG), down 3.6%. LOWER: Yahoo (YHOO), down 3% after downgraded at CRT Capital following second quarter earnings report... Ares Capital (ARCC), down 2.5% after filing to sell 11.85M shares of common stock... Nationstar (NSM), down 2.4% after downgraded at Wells Fargo... Walter Investment (WAC), which was also downgraded at Wells Fargo, down 1.6%.
09:09 EDTGEGeneral Electric-powered Boeing 777X commissioned by Qatar Airways
Subscribe for More Information
09:03 EDTGEQatar Airways commits to additional 50 GE9X-powered Boeing 777x
Subscribe for More Information
08:18 EDTGEGE announces presentation of new flutemetamol PET scan data
Subscribe for More Information
08:10 EDTGEBoeing, Airbus narrow engine choices in move toward efficient jets, WSJ says
Subscribe for More Information
08:03 EDTAAPLApple deal with IBM could drive enterprise sales, says Canaccord
Subscribe for More Information
08:01 EDTAZNAlexion names former AstraZeneca CEO David Brennan to board
Subscribe for More Information
08:00 EDTAAPLInvenSense Orbotech look good into Q2 results, says Oppenheimer
Subscribe for More Information
07:59 EDTAZNTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:14 EDTGSKIsis Pharmaceuticals earns $1M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $27M in upfront and milestone payments for advancing ISIS-TTRRx. If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
06:55 EDTAAPLSurvey shows Samsung losing smartphone ground, Reuters says
Subscribe for More Information
06:38 EDTAAPLApple price target raised to $107 on enterprise opportunity at Goldman
Subscribe for More Information
06:20 EDTAAPLDRAM chip prices likely to increase 10% in July, DigiTimes reports
Subscribe for More Information
06:18 EDTAAPLApple's iPhone orders to benefit Taiwan component maker revenue, DigiTimes says
Subscribe for More Information
06:17 EDTAAPLApple initiated with a Buy at Citigroup
Citigroup believes consensus expectations are underappreciating the upgrade potential of Apple’s installed base. Citi believes Street estimates for 2015 and 2016 are too low and started shares of Apple with a Buy rating and $110 price target.
06:14 EDTAAPLABI Research: More than 2B smartphones to ship in 2018, DigiTimes says
Subscribe for More Information
05:38 EDTGSKGSK, Theravance initiate Phase III IMPACT study
GlaxoSmithKline (GSK) and Theravance (THRX) announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the 'closed' triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease, or COPD. IMPACT is the first pivotal phase III study in a programme to evaluate a once-daily closed triple combination treatment of an inhaled corticosteroid, or ICS; a long-acting muscarinic antagonist, or LAMA; and a long-acting beta2-adrenergic agonist, or LABA, in patients with COPD. The IMPACT study will enrol approximately 10,000 patients and assess whether the combination of FF, or fluticasone furoate, an ICS, UMEC, or umeclidinium, a LAMA, and VI, or vilanterol, a LABA, all delivered in GSK's Ellipta inhaler, can reduce the annual rate of moderate and severe exacerbations compared with two approved once daily COPD treatments, Relvar/Breo Ellipta, FF/VI, which is an ICS/LABA combination, and Anoro Ellipta, UMEC/VI, which is a LAMA/LABA combination.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use